Previous close | 41.26 |
Open | 41.61 |
Bid | 42.98 x 200 |
Ask | 43.02 x 100 |
Day's range | 41.05 - 43.60 |
52-week range | 34.32 - 54.44 |
Volume | |
Avg. volume | 1,079,242 |
Market cap | 6.273B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
4D Molecular Therapeutics (FDMT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.